Breadcrumb

Faculty News

First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma

On February 16, 2024, the Food and Drug Administration approved lifileucel (Amtagvi), the first cancer treatment that uses immune cells called tumor-infiltrating lymphocytes (TILs), for some people with advanced melanoma. TIL therapy was pioneered in the 1980s by Steven A. Rosenberg, M.D., Chief of the Surgery Branch, and the final approval of this treatment has taken years of clinical trial research and ongoing partnerships among multiple institutions.

Read More

Steven Rosenberg receives AACR Award for Lifetime Achievement in Cancer Research

The American Association for Cancer Research (AACR) has awarded Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, the AACR Award for Lifetime Achievement in Cancer Research. He is being recognized for his paramount contributions to cancer research and patient care, most notably his pioneering research in establishing cancer immunotherapy as a major treatment strategy for many cancer types. He will receive the award at the 2024 AACR Annual Meeting. 

Read More

CCR researchers receive an array of HHS awards

Three CCR researchers received prestigious awards from the Department of Health and Human Services on September 28, 2023. They are being recognized for their excellence, dedication and achievements in their respective research fields.

Read More